B-cell depletion limits HTLV-1-infected T-cell expansion and ameliorate HTLV-1-associated myelopathy.
Lv A, Fang Y, Lin X, Chen J, Song H, Wang N, Chen WJ, Fu Y, Li R, Lin Y.
Ann Clin Transl Neurol. 2024 Oct;11(10):2756-2768. doi: 10.1002/acn3.52190. Epub 2024 Aug 26.
Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development.
Navarrete M, Costoya C, Galvez-Cancino F, Peggs KS, Marabelle A, Quezada SA.
Annu Rev Med. 2026 Jan;77(1):239-251. doi: 10.1146/annurev-med-043024-123559. Epub 2025 Nov 13.
Selective STING stimulation in dendritic cells primes antitumor T cell responses.
Jneid B, Bochnakian A, Hoffmann C, Delisle F, Djacoto E, Sirven P, Denizeau J, Sedlik C, Gerber-Ferder Y, Fiore F, Akyol R, Brousse C, Kramer R, Walters I, Carlioz S, Salmon H, Malissen B, Dalod M, Piaggio E, Manel N.
Sci Immunol. 2023 Jan 13;8(79):eabn6612. doi: 10.1126/sciimmunol.abn6612. Epub 2023 Jan 13.
Naive T-cell depletion in stem cell transplantation.
Bleakley M.
Blood Adv. 2020 Oct 13;4(19):4980. doi: 10.1182/bloodadvances.2020001888.
Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.
Mohty M.
Leukemia. 2007 Jul;21(7):1387-94. doi: 10.1038/sj.leu.2404683. Epub 2007 Apr 5.
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P, Testa JS, Ponticiello R, Brodeur S, Heidrich B, Packman K, Singh S, Attar R, Elsayed Y, Philippar U.
Blood. 2026 Feb 19;147(8):834-847. doi: 10.1182/blood.2025030027.
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
Lax BM, Palmeri JR, Lutz EA, Sheen A, Stinson JA, Duhamel L, Santollani L, Kennedy A, Rothschilds AM, Spranger S, Sansom DM, Wittrup KD.
Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2300895120. doi: 10.1073/pnas.2300895120. Epub 2023 Jul 24.
T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock.
Hazenberg MD, Hamann D, Schuitemaker H, Miedema F.
Nat Immunol. 2000 Oct;1(4):285-9. doi: 10.1038/79724.
Cutting Edge: Low-dose Recombinant IL-2 Treatment Prevents Autoantibody Responses in Systemic Lupus Erythematosus via Regulatory T Cell-independent Depletion of T Follicular Helper Cells.
Santana S, Papillion A, Foote JB, Bachus H, León B, De Miguel C, Ballesteros-Tato A.
J Immunol. 2024 Oct 15;213(8):1053-1060. doi: 10.4049/jimmunol.2400264.
PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors.
Abdelhamed S, Zhang X, Zeng W, Grogan B, Schilperoort L, James R, Burley KC, Sarrett SM, Bou L, Raha P, Olson DJ, Sigurjonsson HL, Dominguez MMC, Nicholas T, Neff-LaFord HD, Fishburn J, Lim AR, Diolaiti D, Gupta P, Abrahams CL, Carosino CM, Heiser RA, Gardai SJ, Levengood MR.
Mol Cancer Ther. 2025 Jul 2;24(7):963-975. doi: 10.1158/1535-7163.MCT-25-0101.
